Variable | Malignant | Borderline | Benign | Reference level | P-value |
---|---|---|---|---|---|
Number | 64 | 64 | 156 | ||
W (109/L) | 6.55 ± 3.26 | 5.91 ± 1.31 | 5.79 ± 1.91 | 3.5–9.5 | 0.0549 |
N (109/L) | 4.58 ± 3.20 | 3.54 ± 1.21 | 2.82 ± 1.42 | 1.8–6.3 | < 0.001abc |
L (109/L) | 1.51 ± 0.54 | 1.86 ± 0.55 | 2.10 ± 0.62 | 1.1–3.2 | < 0.001abc |
Mo (109/L) | 0.35 ± 0.15 | 0.36 ± 0.10 | 0.36 ± 0.13 | 0.1–0.6 | 0.868 |
PLT (109/L) | 253.8 ± 83.24 | 242.9 ± 59.16 | 189.8 ± 56.40 | 125–350 | < 0.001bc |
PDW (fL) | 13.33 ± 2.61 | 13.56 ± 2.10 | 13.86 ± 2.95 | 9.6–15.2 | 0.5594 |
RDW (%) | 42.63 ± 5.33 | 41.48 ± 2.36 | 42.10 ± 2.98 | 41.2–53.6 | 0.3279 |
PLR | 193.3 ± 103.35 | 140.2 ± 49.61 | 80.61 ± 25.85 | / | < 0.001abc |
NLR | 3.87 ± 6.02 | 2.15 ± 1.39 | 1.19 ± 0.47 | / | < 0.001abc |
MLR | 0.27 ± 0.20 | 0.21 ± 0.07 | 0.15 ± 0.05 | / | < 0.001abc |
CA125 (U/ml) | 90.57 ± 75.22 | 39.48 ± 47.37 | 12.41 ± 3.37 | 0–35 | < 0.001abc |
HE4 (pmol/L) | 128.00 ± 186.14 | 58.64 ± 30.44 | 52.56 ± 11.01 | premenopause < 70 postmenopause< 140 | < 0.001ac |